CAR-NK Cell Targeting Cotinine for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapeutic agents for cancer treatment face limitations such as high production costs, persistent toxicity, non-specific attacks on healthy tissues, and autoimmune risks, necessitating the development of more efficient and safer cancer therapies.
Innovation Solution
A natural killer cell expressing a chimeric antigen receptor (CAR) with an antigen binding domain specific to cotinine, which includes a transmembrane domain and intracellular signaling domain, allowing for targeted cancer cell recognition and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cell therapy is used to treat cancer, then therapeutic effectiveness is improved, but production cost increases and persistent toxicity occurs
Solution Approach 1:
The patent segments the therapeutic approach by using off-the-shelf NK cells from healthy donors rather than customizing CAR-T cells for each patient. This standardization enables batch production and reduces manufacturing complexity while maintaining therapeutic effectiveness through the engineered CAR expression on NK cells
Solution Approach 2:
The patent employs readily available NK cells from healthy donors as a disposable therapeutic resource. These cells can be produced in batches, stored, and administered without requiring complex personalized manufacturing processes, thereby reducing production costs while maintaining therapeutic efficacy
2Reliability
If CAR-T cell therapy is used to treat cancer, then therapeutic effectiveness is improved, but non-specific attacks on healthy tissues occur causing toxicity
Solution Approach 1:
The patent applies local quality by engineering CAR receptors with specific antigen-binding domains that recognize cancer-associated antigens with high specificity. This localized molecular recognition ensures that NK cells attack only target cancer cells expressing the specific antigen, minimizing non-specific attacks on healthy tissues
Solution Approach 2:
The patent incorporates feedback mechanisms through the CAR structure itself, which requires specific antigen recognition to activate the NK cell. This built-in feedback system ensures that therapeutic action is triggered only when cancer cells are detected, preventing unnecessary attacks on healthy tissues
3Reliability
If CAR-T cell therapy is used to treat cancer, then therapeutic effectiveness is improved, but autoimmune risks increase
Solution Approach 1:
The patent uses NK cells as a universal therapeutic platform that can be applied across multiple cancer types by simply changing the CAR antigen-targeting specificity. This multi-functional approach allows a single cell product to serve multiple therapeutic purposes, reducing the need for multiple specialized treatments that could increase autoimmune risks
4Reliability
If CAR-T cell therapy is used to treat cancer, then cancer cell antigen-recognizing ability is improved, but device complexity increases
Solution Approach 1:
The patent segments the complex therapeutic development process into standardized NK cell production with modular CAR engineering. This segmentation allows for systematic optimization of antigen recognition while maintaining manageable complexity through standardized manufacturing protocols and off-the-shelf cell products
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CAR-NK cell effectively targets tumor tissues with high specificity and efficiency, minimizing toxicity and enabling the use of a general-purpose therapeutic agent with reduced development and treatment costs, while providing a switchable therapeutic response.
Implementation Method 1
an antigen binding domain, which is a domain that specifically binds to cotinine
Data Source
AI summary
Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.